Laurus Labs Posts Robust FY26 Growth, PAT Surges 148%

Consolidated revenue from operations for FY 2025-26 reached ₹ 6,813 crore, marking a 23% year-on-year increase. Profit after tax (PAT) saw a significant surge of 148%, reaching ₹ 889 crore. The company's EBITDA grew by 64% to ₹ 1,826 crore, with a healthy EBITDA margin of 26.8%.

Reader Takeaway: Strong revenue and profit growth driven by CDMO and Affordable Medicines, while restructuring progresses.

What just happened

Laurus Labs announced its financial results for FY 2025-26, showcasing substantial top-line and bottom-line growth. Revenue from operations increased by 23% to ₹ 6,813 crore. The company’s profitability significantly improved, with EBITDA growing 64% to ₹ 1,826 crore and PAT jumping 148% to ₹ 889 crore. The net debt-to-EBITDA ratio improved to 1.3x from 2.3x in the previous fiscal year.

Why this matters

This strong financial performance indicates effective execution of the company's strategy, particularly in its CDMO and Affordable Medicines segments. The substantial PAT growth suggests improved operational efficiencies and product mix. The strengthening balance sheet with reduced debt leverage is positive for financial stability and future growth prospects. Additionally, the approved composite scheme of arrangement signals strategic moves to streamline operations.

The backstory

Laurus Labs has been focusing on expanding its capabilities in contract development and manufacturing (CDMO) and its Affordable Medicines business, which includes APIs and finished dosage forms (FDF). In FY 2025-26, the CDMO segment reported revenue of ₹ 2,080 crore, driven by growth in small molecules and bio-CDMO. The Affordable Medicines segment contributed ₹ 4,733 crore.

What changes now

The Board has approved a Composite Scheme of Arrangement, which involves demerging LSPL's Unit-1 into Sriam Labs and amalgamating the rest of LSPL with Laurus Labs. This is expected to be completed by September 2026. The company also invested ₹ 1,070 crore in capital expenditure for expanding CDMO, formulations, fermentation, and biologics capabilities. A large land parcel of 532 acres in Visakhapatnam has been secured for future expansion.

Risks to watch

Key watch points include potential impacts from trade policy, pricing pressures, and geopolitical tensions on global supply chains. Near-term performance could also be influenced by procurement cycles and product mix shifts.

Peer comparison

While specific peer data isn't provided in the filing, Laurus Labs' performance in FY 2025-26 shows significant growth in revenue and profitability, alongside a reduction in debt-to-EBITDA, which is generally viewed favorably by investors in the pharmaceutical and contract manufacturing sectors.

Context metrics (time-bound)

• Revenue from Operations (FY 2025-26): ₹ 6,813 crore (up 23% YoY)
• EBITDA (FY 2025-26): ₹ 1,826 crore (up 64% YoY)
• PAT (FY 2025-26): ₹ 889 crore (up 148% YoY)
• Net Debt-to-EBITDA Ratio: 1.3x (improved from 2.3x in FY 2024-25)
• Operating Cash Flow: ₹ 1,624 crore (improved)
• Capital Expenditure (FY 2025-26): ₹ 1,070 crore

What to track next

Investors will be keen to monitor the progress of the corporate restructuring scheme and its timely completion. Execution of major capacity expansion projects and sustained growth in the CDMO and Affordable Medicines segments will be crucial indicators to watch.